Pharmacoeconomics refers to the scientific discipline that compares the value of one pharmaceutical drug or drug therapy to another. Cost variation analysis on various brands of corticosteroids available in the Indian market provides information on price differences between these brands. It can decrease the price fluctuations in the market. The novelty of the current study is that it could help frame guidelines regarding price capping for various drug companies. The current study assessed cost variation analysis among all corticosteroid brands available in India. The objectives include assessment of the dose, no. of brands available, minimum and maximum price, cost ratio, percentage cost variation, and mean price of each medication. This study used the Drug Today book dated Jan 2022(DT 114), published annually. The study was done in the Department of Pharmacology at a tertiary care center named Government Medical College, Ongole, Andhra Pradesh, India. The study was done for 1 week during March 2023. All corticosteroid brands mentioned in Drug Today book, including topical, inhalational, oral, and parenteral dosage forms, both monotherapy and combination therapies, were included. Results showed a significant difference in the mean price of various oral and parenteral corticosteroid brands available in India. Price variation is maximum for prednisolone among oral preparations and triamcinolone among parenteral preparations. Our study concludes that a huge variation in pricing is seen in the Indian context for various corticosteroids. Physicians should also be made aware of the prices of various medications while encouraging them to prescribe generic medicines.  It suggests that prescribing drugs in generic names will allow the pharmacist to dispense suitable and cost effective drugs to the patient.

Reference

1.          Walley T, Haycox A. Pharmacoeconomics: basic concepts and terminology. Br J Clin Pharmacol. 1997;43(4):343-8. doi: 10.1046/j.1365-2125.1997.00574.x. (PMC Free article). PMID: 9146844 [CrossRef] Google Scholar.

2.          McIntosh E, Luengo-Fernandez R. Economic evaluation. Part 1: Introduction to the concepts of economic evaluation in health care. J Fam Plann Reprod Health Care. 2006;32(2):107-12. doi: 10.1783/147118906776276549 PMID: 16824302 [CrossRef] Google Scholar.

3.          Murphy EM, Rodis JL, Mann HJ. Three ways to advocate for the economic value of the pharmacist in health care. J Am Pharm Assoc (2003). 2020;60(6):e116-24. doi: 10.1016/j.japh.2020.08.006 PMID: 32863183.

4.          Meena DK, Jayanthi M. Cost analysis of different antibiotic brands available in the Indian market concerning National list of essential medicines. Indian J Community Med. 2021 January-March;46(1):93-6. doi: 10.4103/ijcm.IJCM_296_20. PMID: 34035585 PMCID: PMC8117914.

5.          Advani M, Seetharaman R, Pawar M, Naik B. A cost-variation analysis of drugs available in the Indian market for managing diabetic nephropathy. Cureus. 2022 5 October;14(10):e29942. doi: 10.7759/cureus.29942 PMID: 36348866 PMCID: PMC9635218.

6.          Sarangi SC, Kaur N, Tripathi M, Gupta YK. Cost analysis study of neuropsychiatric drugs: role of National List of Essential Medicines, India. Neurol India. 2018 September-October;66(5):1427-33. doi: 10.4103/0028-3886.241345 PMID: 30233018.

7.          Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus. 2020 5 May;12(5):e7964. doi: 10.7759/cureus.7964 PMID: 32523821 PMCID: PMC7273361.

8.          Tonin FS, Aznar-Lou I, Pontinha VM, Pontarolo R, Fernandez-Llimos F. Principles of pharmacoeconomic analysis: the case of pharmacist-led interventions. Pharm Pract (Granada). 2021;19(1):2302. doi: 10.18549/PharmPract.2021.1.2302 PMID: 33727994.

9.          Elliott RA, Putman K, Davies J, Annemans L. A review of the methodological challenges in assessing the cost-effectiveness of pharmacist interventions. Pharmacoeconomics. 2014;32(12):1185-99. doi: 10.1007/s40273-014-0197-z PMID: 25145799 [CrossRef] Google Scholar.

10.          Pontinha VM, Wagner TD, Holdford DA. Point-of-care testing in pharmacies-An evaluation of the service from the lens of resource-based theory of competitive advantage. J Am Pharm Assoc (2003). 2021;61(2):e45-54. doi: 10.1016/j.japh.2020.11.005 PMID: 33309067.

11.          Newman TV, San-Juan-Rodriguez A, Parekh N, et al. Impact of community pharmacist-led interventions in chronic disease management on clinical, utilization, and economic outcomes: An umbrella review. Res Soc Admin Pharm. 2020;16(9):1155-65. doi: 10.1016/j.sapharm.2019.12.016 PMID: [CrossRef]. Google Scholar.

12.          National health accounts; 2004-05 [Internet]. People’s Archive of Rural India. 2018. Accessed 11 May 2023. https://ruralindiaonline.org/library/resource/national-health-accounts-2004-05/.

13.          The drugs (prices control) order; 2013 [Internet]. Nic.in. Accessed